Phase II trial of gemcitabine monotherapy in the third or further line for pretreated patients with advanced non-small cell lung cancer
Phase 2
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000017791
- Lead Sponsor
- Dept.Repiratory Medicine, Osaka Police Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 21
Inclusion Criteria
Not provided
Exclusion Criteria
1) A history of gemcitabine treatment 2) Current or previous history of pulmonary fibrosis, interstitial pneumonitis or drug-induced pneumonia, revealed by chest X-ray film 3) Concurrent thoracic radiotherapy 4) A history of severe hypersensitivity against gemcitabine 5) Another active advanced malignancy that requires any concurrent treatment with treatment for lung cancer 6) Pleural effusion, ascites or peri-cardiac effusion requiring dranage. 7) Problematic complications 8) Pregnant or lactation women, or women with known or suspected pregnancy and men who want let to pregnancy 9) Decision of ineligibility by a physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression-free survival(PFS)
- Secondary Outcome Measures
Name Time Method Response rate (RR), Overall survival (OS), 1yr-survival rate, adverse effects, QOL assessment